The “Curse of Bigness” Today

By Ben Gomes-Casseres | Originally in PBS MAKING SEN$E | Portions of this article are from the author’s article in Harvard Business Review, which you can read here.

Editor’s Note: Ben Gomes-Casseres, author of “Remix Strategy: The Three Laws of Business Combinations,” pulls lessons from a trio of recent high-profile deal cancellations: Halliburton-Baker Hughes, Pfizer-Allergan and Staples-Office Depot.

This month marked the 100th anniversary of Louis Brandeis’ confirmation to the U.S. Supreme Court. Reading his passionate writings on the “curse of bigness” makes me wonder what Brandeis would think of today’s big mergers.

As it happens, anti-trust authorities have been active of late, questioning many of those mergers. And several have been stopped dead in their tracks — to the disappointment of the investment-banker descendants of the money houses that were Brandeis’s nemesis in the early 20th century.

Some of the recent deals were too rich or too clever for their own good, and others pushed industry consolidation one bridge too far.

What lies behind the recent wave of antitrust actions? Politics, perhaps — but the Obama administration has not been more active stopping mergers than previous administrations. But some of the recent deals were too rich or too clever for their own good, and others pushed industry consolidation one bridge too far. And probably ‘tis just the season for it — the wave of antitrust actions may just stem from last year’s bumper crop of merger announcements.

Let’s look at a trio of recent high-profile deal cancellations: Halliburton-Baker Hughes, Pfizer-Allergan and Staples-Office Depot. These mergers span a wide swath of American industry — from to oil and gas to pharmaceuticals and big-box retailing. This diversity suggests how varied the reasons are behind today’s mergers.

The classic reason for firms combining their assets is to remix them to create new value. But who captures that new value? Usually shareholders do so to some extent, otherwise they would not approve the merger. Beyond that, do consumers benefit or not? What is the impact on competition and rival companies? More broadly, is the new value truly a net benefit to society, or is it a transfer from one group to another? These larger societal questions are the kind exercised by Louis Brandeis and that today are addressed by various regulatory bodies.

READ MORE: Column: Why mergers are booming

A careful look at these three deals shows how regulators think about these questions and leads to lessons for managers contemplating mergers in the future. (Several health care insurance mergers are up for review this summer, such as Cigna-Anthem.)

The Halliburton-Baker Hughes deal was a classic case of a bridge too far. And they knew it. Baker Hughes had resisted Halliburton’s overtures for months before agreeing to the deal, fearing that it would not pass anti-trust muster. It accepted the offer in the end only with a large break-up fee of $3.5 billion.

It did not take the Department of Justice much figuring to show that the merger of the number two and number three player oil field services would concentrate selling power substantially in 23 specific markets, from drilling fluids to drill bits. This would reduce options for customers (huge oil companies themselves) and could reduce innovation, they reasoned. And crucially, the Department of Justice did not see benefits to the concentration — no countervailing pro-competitive or efficiency effects that might have tilted the balance in favor of approval. Open and shut case, they said. It took only a few weeks for the deal makers to scuttle their plan, without much of a fight.

The Pfizer-Allergan deal was canceled even more quickly — within 24 hours of the U.S. Treasury’s announcement of new rules that wiped out the value the deal offered shareholders. Moving a company’s headquarters to low-tax havens through a merger is not in itself a fancy trick — hundreds of companies have done these inversions. But this one was a bit too clever. To pass muster, the foreign partner in such a deal must be large enough to hold on to at least a 40 percent share of the merged entity. Pfizer is big, so the foreign partner had to be sizable itself. To reach the threshold, Pfizer ended up granting Allergan a huge premium, much beyond what would be justified by projected synergies. Without the tax benefits of the inversion, therefore, the numbers in the deal simply did not add up. (Other deals, such as the medical device merger between Covidien and Medtronic in 2014, survived even after some of their tax benefits were denied, because they came with substantial non-tax benefits too.)
The first lesson from these deal busts is this: If you wish to consolidate, be sure it will create value for customers and society, not just for shareholders and bankers. The Department of Justice’s own “Antitrust Guidelines for Collaborations Among Competitors” admits that “in order to compete in modern markets, competitors sometimes need to collaborate . . . Such collaborations often are not only benign but procompetitive.” Nevertheless, the guidelines continue, certain agreements that are highly likely to harm competition and have no procompetitive benefits may be ruled as unlawful under the “rule of reason, which involves a factual inquiry into an agreement’s overall competitive effect.”
The Staples-Office Depot deal was the only of these three to put that rule of reason to the test in court. This merger of the number one and number two office supply big box chain admitted that, yes, competition will be suppressed and consolidation will follow. But this competition-reducing effect was to be counter-balanced by the new Staples being able to invest more robustly in online businesses, which would strengthen competition in that growing market (e.g. competition with Ultimately, Staples and Office Depot argued, the positive effect of stronger competition online would outweigh the reduction in brick-and-mortar competition. But they failed to convince the court that they were ultimately creating value for society, not just retrenching and closing stores. In a puzzling move, they refused to call any witnesses to defend their position — they simply failed to make their case.

This case highlights the second lesson of the season: It is tough to argue that long term good will come from short term pain. Corporate leaders in the U.S. now see that there are greater hurdles to cross in thinking through, structuring and presenting such strategic arguments. In the end, that is a good thing.

The third lesson from the merger-busting climate is that alternatives to merger will become more attractive. The global airline industry for a long time has managed to do with alliances what other industries do with mergers – because they are blocked from cross-border mergers for the most part.

Often, asset swaps, joint ventures and divestments can serve to focus a business better than a big merger. For example, pharmaceutical giants Novartis and GlaxoSmithKline completed a complex deal last year that involved a swapping of assets to focus each business better, a divestment of some assets to third parties and a new joint venture created to consolidate similar businesses. These transactions were sharply defined combinations that did not require a full-frontal merger of the two parent companies. Smart deals such as this one can serve the purpose of remixing assets without incurring the costs of “bigness.”
Since Teddy Roosevelt and Louis Brandeis, the United States has seen a continual push-and-pull between anti-trust enforcement and merger waves. The latter always crest, as they have appear to have done now, and then the former loom larger. But the underlying drivers of business combinations do not disappear – they will just get channeled in new ways.